{"id":805777,"date":"2026-04-30T10:22:01","date_gmt":"2026-04-30T10:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=805777"},"modified":"2026-04-30T10:22:01","modified_gmt":"2026-04-30T10:22:01","slug":"psoriatic-arthritis-market-strong-pharma-growth-forecast-through-2034-delveinsight-abbvie-novartis-janssen-research-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-bio","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-strong-pharma-growth-forecast-through-2034-delveinsight-abbvie-novartis-janssen-research-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-bio_805777.html","title":{"rendered":"Psoriatic Arthritis Market: Strong Pharma Growth Forecast Through 2034 \u2013 DelveInsight | AbbVie, Novartis, Janssen Research, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Bio"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777488539.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriatic Arthritis Market: Strong Pharma Growth Forecast Through 2034 &ndash; DelveInsight | AbbVie, Novartis, Janssen Research, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Bio\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1777488539.jpg\" alt=\"Psoriatic Arthritis Market: Strong Pharma Growth Forecast Through 2034 &ndash; DelveInsight | AbbVie, Novartis, Janssen Research, Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Bio\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Psoriatic Arthritis Companies in the market include &#8211; Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research &#038; Development, LLC, MoonLake Immunotherapeutics AG, and others.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2034&Prime;<\/strong> report offers an in-depth understanding of the Psoriatic Arthritis, historical and forecasted epidemiology as well as the Psoriatic Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Psoriatic Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Psoriatic Arthritis Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Psoriatic Arthritis Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Psoriatic Arthritis market size is estimated to grow approximately <strong>USD 15 billion by 2032<\/strong> with a significant CAGR during the study period (2020-2034).<\/p>\n<\/li>\n<li>\n<p><strong>In March 2026, Bristol Myers Squibb<\/strong> announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu for the treatment of adults with active psoriatic arthritis. Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor and represents the first therapy in this class to receive approval for PsA.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2025, Teva Pharmaceuticals and Alvotech<\/strong> announced that the FDA has approved SELARSDI&trade; (ustekinumab-aekn) injection as an interchangeable biosimilar to the reference biologic Stelara. As of April 30, 2025, SELARSDI is available in all formulations equivalent to the reference product for treating both adult and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn&rsquo;s disease, and ulcerative colitis.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Celltrion announced the U.S. launch of STEQEYMA&reg; (ustekinumab-stba), a biosimilar to STELARA&reg; (ustekinumab), following FDA approval in December 2024. STEQEYMA is approved for the same indications as STELARA, offering consistent treatment for patients and healthcare providers.<\/p>\n<\/li>\n<li>\n<p>The current treatment landscape for psoriatic arthritis includes therapies such as HUMIRA (adalimumab), OTEZLA (apremilast), COSENTYX (secukinumab), CIMZIA (certolizumab pegol), and BIMZELX (bimekizumab), among others.<\/p>\n<\/li>\n<li>\n<p>Several promising Psoriatic Arthritis therapies, including SOTYKTU (deucravacitinib), ILUMYA (tildrakizumab), and others, are currently in late-stage clinical development.<\/p>\n<\/li>\n<li>\n<p>For patients with psoriatic arthritis who do not respond to TNF inhibitor monotherapy, IL-17 inhibitors are generally preferred over IL-12\/23 inhibitors, abatacept, or tofacitinib. However, IL-12\/23 inhibitors may be a suitable option for individuals with coexisting inflammatory bowel disease or for those who prefer less frequent dosing compared to IL-17 inhibitors.<\/p>\n<\/li>\n<li>\n<p>Key companies active in the Psoriatic Arthritis market include developers of therapies such as bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB), among others.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s analysis, Psoriatic Arthritis was observed to affect females more frequently than males. In 2023, females accounted for approximately 15% more PsA cases compared to males.<\/p>\n<\/li>\n<li>\n<p>DelveInsight&rsquo;s analysis indicates that in 2023, the majority of Psoriatic Arthritis cases were of moderate severity, comprising approximately 60% of cases, followed by severe and mild forms.<\/p>\n<\/li>\n<li>\n<p>In the US in 2023, the age group 50&ndash;59 years had the highest prevalence of Psoriatic Arthritis, while the 18&ndash;29 age group had the lowest number of cases.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&#8217;s analysis, in 2023, Germany had the highest number of Psoriatic Arthritis cases among the EU4 countries and the UK, while Spain reported the lowest.<\/p>\n<\/li>\n<li>\n<p>National Psoriatic Foundation estimates that about one-third (30%) of people with psoriasis go on to develop psoriatic arthritis, impacting as many as 2.4 million individuals in the United States. The condition can arise at any age.<\/p>\n<\/li>\n<li>\n<p>According to a 2024 study by Brent et al., the prevalence of psoriatic arthritis among individuals with psoriasis increases over time reaching 1.7% at 5 years, 3.1% at 10 years, 5.1% at 20 years, and 20.5% at 30 years. Overall, about 19.7% of psoriasis patients develop psoriatic arthritis, with higher rates observed in adults (21.6%) compared to children (3.3%).<\/p>\n<\/li>\n<li>\n<p><strong>Key Psoriatic Arthritis Companies:<\/strong> Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research &amp; Development, LLC, MoonLake Immunotherapeutics AG, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Psoriatic Arthritis Therapies: I<\/strong>LUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab and others<\/p>\n<\/li>\n<li>\n<p>The Psoriatic Arthritis epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases<\/p>\n<\/li>\n<li>\n<p>The Psoriatic Arthritis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriatic Arthritis pipeline products will significantly revolutionize the Psoriatic Arthritis market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects some individuals with psoriasis, a skin disease. PsA causes joint pain, stiffness, and swelling, and can also affect other parts of the body, including the skin, nails, and eyes. The exact cause is unknown, but it involves an overactive immune system attacking healthy tissue. Diagnosis typically involves clinical evaluation, imaging, and blood tests.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Psoriatic Arthritis Market Report <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Psoriatic Arthritis market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalence of Psoriatic Arthritis<\/p>\n<\/li>\n<li>\n<p>Prevalent Cases of Psoriatic Arthritis by severity<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalence of Psoriatic Arthritis<\/p>\n<\/li>\n<li>\n<p>Diagnosed Cases of Episodic and Chronic Psoriatic Arthritis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Psoriatic Arthritis Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriatic Arthritis market or expected to get launched during the study period. The analysis covers Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Psoriatic Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>ILUMYA: Sun Pharma<\/p>\n<\/li>\n<li>\n<p>Deucravacitinib: Bristol-Myers Squibb<\/p>\n<\/li>\n<li>\n<p>Bimekizumab: UCB Biopharma<\/p>\n<\/li>\n<li>\n<p>Izokibep: Affibody AB<\/p>\n<\/li>\n<li>\n<p>SUNPG18_07: Sun Pharmaceutical Industries Limited<\/p>\n<\/li>\n<li>\n<p>VTX958: Ventyx Biosciences, Inc<\/p>\n<\/li>\n<li>\n<p>ATI-450: Aclaris Therapeutics, Inc.<\/p>\n<\/li>\n<li>\n<p>Risankizumab: AbbVie<\/p>\n<\/li>\n<li>\n<p>Upadacitinib: AbbVie<\/p>\n<\/li>\n<li>\n<p>AIN457: Novartis<\/p>\n<\/li>\n<li>\n<p>Ustekinumab: Janssen Research &amp; Development, LLC<\/p>\n<\/li>\n<li>\n<p>Sonelokimab: MoonLake Immunotherapeutics AG<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Psoriatic Arthritis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Psoriatic Arthritis Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rising prevalence of psoriatic arthritis and associated autoimmune conditions globally<\/p>\n<\/li>\n<li>\n<p>Increasing awareness and early diagnosis supported by improved screening tools<\/p>\n<\/li>\n<li>\n<p>Strong adoption of advanced biologics (TNF inhibitors, IL-17, IL-23 inhibitors)<\/p>\n<\/li>\n<li>\n<p>Growing development of targeted therapies such as JAK inhibitors and novel monoclonal antibodies<\/p>\n<\/li>\n<li>\n<p>Expanding research and development activities with a robust clinical pipeline<\/p>\n<\/li>\n<li>\n<p>Improved healthcare infrastructure and reimbursement policies in developed markets<\/p>\n<\/li>\n<li>\n<p>Shift toward personalized and precision medicine approaches<\/p>\n<\/li>\n<li>\n<p>Increased patient access due to the availability of biosimilars<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriatic Arthritis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>High cost of biologic and advanced therapies limiting affordability<\/p>\n<\/li>\n<li>\n<p>Stringent regulatory requirements leading to long approval timelines<\/p>\n<\/li>\n<li>\n<p>Variability in disease presentation complicating diagnosis and treatment selection<\/p>\n<\/li>\n<li>\n<p>Potential side effects and safety concerns with long-term biologic use<\/p>\n<\/li>\n<li>\n<p>Loss of treatment response or inadequate efficacy in some patients<\/p>\n<\/li>\n<li>\n<p>Limited access to specialized care in emerging and low-income regions<\/p>\n<\/li>\n<li>\n<p>Competitive market landscape leading to pricing pressures<\/p>\n<\/li>\n<li>\n<p>Challenges in patient adherence due to chronic treatment regimens<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Psoriatic Arthritis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2020&ndash;2034<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Psoriatic Arthritis Companies:<\/strong> Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research &amp; Development, LLC, MoonLake Immunotherapeutics AG, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Psoriatic Arthritis Therapies:<\/strong> ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others<\/p>\n<\/li>\n<li>\n<p><strong>Psoriatic Arthritis Therapeutic Assessment:<\/strong> Psoriatic Arthritis current marketed and Psoriatic Arthritis emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Psoriatic Arthritis Market Dynamics:<\/strong> Psoriatic Arthritis market drivers and Psoriatic Arthritis market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Psoriatic Arthritis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Psoriatic Arthritis Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Psoriatic Arthritis companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Psoriatic Arthritis Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Psoriatic Arthritis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">4. Psoriatic Arthritis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Psoriatic Arthritis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Psoriatic Arthritis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Psoriatic Arthritis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Psoriatic Arthritis<\/p>\n<p style=\"text-align: justify;\">9. Psoriatic Arthritis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Psoriatic Arthritis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Psoriatic Arthritis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Psoriatic Arthritis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Psoriatic Arthritis Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify;\">14. Psoriatic Arthritis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Psoriatic Arthritis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Psoriatic Arthritis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Psoriatic Arthritis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Psoriatic Arthritis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriatic-arthritis-market-strong-pharma-growth-forecast-through-2034-delveinsight-abbvie-novartis-janssen-research-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-bio\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriatic-arthritis-market-strong-pharma-growth-forecast-through-2034-delveinsight-abbvie-novartis-janssen-research-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-bio\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Psoriatic Arthritis Companies in the market include &#8211; Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research &#038; Development, LLC, MoonLake Immunotherapeutics AG, and others. DelveInsight&rsquo;s &ldquo;Psoriatic Arthritis Market Insights, Epidemiology, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-market-strong-pharma-growth-forecast-through-2034-delveinsight-abbvie-novartis-janssen-research-sun-pharma-bristolmyers-squibb-ucb-biopharma-affibody-ab-ventyx-bio_805777.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-805777","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/805777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=805777"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/805777\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=805777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=805777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=805777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}